Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals

Set Alert for Deals

Amneal Takes Control Of AvKARE In US

Amneal has acquired a majority stake in manufacturer and wholesaler AvKARE, giving the firm access to the “large, complex and growing federal healthcare market.”

Deals Strategy

Lannett Reports Insulin Glargine Trial Success

Lannett’s Phase I trial for biosimilar insulin glargine has met “all primary endpoints,” the company has announced. The rival to Sanofi’s Lantus is being developed by Lannett with partner HEC through a deal for which financial details have just been revealed.

Biosimilars United States

Gene Techno Collaborates With Kishi Kasei On Aflibercept

Gene Techno Science and Kishi Kasei have struck a deal to jointly develop a Japanese aflibercept biosimilar rival to Eylea.

Deals Biosimilars

Krka Sets Out Strategy In Multiple Markets

Krka has revealed its new growth strategy for 2020-2024, including growing through joint ventures, partnerships and acquisitions and focusing on European, central Asian and Chinese markets. At the same time, the Slovenian firm has reported that its sales jumped by 12% in the first nine months of 2019.

Business Strategies Strategy

Egypt’s Rameda Prices Public Offering

Through an initial public offering, Egyptian branded generics supplier Rameda intends to raise funds to buy both products and companies in the Middle East and North Africa.


Business Strategies Middle East and Africa

Granules May Be Next Private Equity Target

A recent focus on high-margin generic formulations, strong contract manufacturing business, and expected cash inflow from stake sales in joint ventures could make Granules India an attractive buy for private equity funds.

Deals M & A
See All
UsernamePublicRestriction

Register